tiprankstipranks
Trending News
More News >
Adicet Bio (ACET)
NASDAQ:ACET
Advertisement

Adicet Bio (ACET) AI Stock Analysis

Compare
714 Followers

Top Page

ACET

Adicet Bio

(NASDAQ:ACET)

Rating:27Underperform
Price Target:
Adicet Bio faces significant financial challenges and technical weaknesses, with no revenue and ongoing losses as critical concerns. The poor valuation further impacts the stock's appeal. While the new board appointment is positive, it does not mitigate the substantial risks present in the company’s financials and market performance.
Positive Factors
Financial Stability
The cash position of the company is strong, which supports its operational stability.
Product Development
Adicet is developing ADI-212, a PSMA targeting candidate for prostate cancer, which has shown anti-tumor efficacy in studies.
Regulatory Approval
ADI-001 has been granted FDA Fast Track Designation for the treatment of adult patients with refractory systemic lupus erythematosus, systemic sclerosis, and relapsed or refractory class III or class IV lupus nephritis.
Negative Factors
Market Competition
The extremely competitive nature of the landscape for ADI-001 in autoimmune diseases is noted.
Workforce Management
The management recently announced a reduction in its workforce by approximately 30%.

Adicet Bio (ACET) vs. SPDR S&P 500 ETF (SPY)

Adicet Bio Business Overview & Revenue Model

Company DescriptionAdicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
How the Company Makes MoneyAdicet Bio primarily makes money through the development and commercialization of its allogeneic gamma delta T cell therapies for cancer treatment. The company generates revenue from partnerships and collaborations with other pharmaceutical companies, as well as through grants and funding aimed at advancing its research and development efforts. Additionally, Adicet Bio may earn income from licensing agreements, where it allows other companies to utilize its proprietary technology in exchange for upfront payments, milestone payments, and potential royalties on future products. The success of these revenue streams is significantly influenced by the company's ability to bring its therapeutic candidates to market and establish strong industry collaborations.

Adicet Bio Financial Statement Overview

Summary
Adicet Bio's financial performance is weak, with no revenue generation, ongoing losses, and negative cash flow. This points to significant operational and financial challenges despite a strong cash position.
Income Statement
20
Very Negative
Adicet Bio's income statement reflects significant challenges with no total revenue reported in the recent year, leading to a gross profit margin of 0%. The consistent net losses over the years and a declining EBIT indicate ongoing operational inefficiencies. The company has not shown recent revenue growth, presenting a concerning outlook for profitability.
Balance Sheet
40
Negative
The balance sheet shows some stability with a healthy equity position due to a positive stockholders' equity. However, the company carries a debt level that is notable, though it's offset by a substantial cash position. Despite these factors, the equity ratio suggests some financial risk due to high liabilities compared to assets.
Cash Flow
35
Negative
The cash flow statement highlights negative operating cash flow and free cash flow, indicating cash outflows from operations. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is unfavorable, reflecting cash management issues. The reliance on financing activities to cover deficits is a potential area of concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.51M0.000.0024.99M9.73M17.90M
Gross Profit-1.62M-6.47M-6.10M24.99M9.73M17.90M
EBITDA-118.27M-110.65M-136.53M-64.70M-60.41M-37.41M
Net Income-118.64M-117.12M-142.66M-69.79M-62.00M-36.68M
Balance Sheet
Total Assets162.97M220.22M207.29M330.69M338.94M153.84M
Cash, Cash Equivalents and Short-Term Investments34.72M176.30M159.71M257.66M277.54M94.61M
Total Debt15.36M17.23M20.92M21.02M20.94M21.64M
Total Liabilities29.60M33.61M37.12M38.35M35.81M44.01M
Stockholders Equity133.37M186.61M170.18M292.34M303.13M109.83M
Cash Flow
Free Cash Flow-100.25M-93.50M-98.18M-61.55M-64.10M-42.54M
Operating Cash Flow-98.14M-92.38M-93.72M-44.77M-51.05M-41.55M
Investing Cash Flow-88.61M-119.24M-4.46M-16.78M-2.80M115.22M
Financing Cash Flow203.82K111.31M236.00K41.51M242.69M303.00K

Adicet Bio Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.71
Price Trends
50DMA
0.70
Positive
100DMA
0.68
Positive
200DMA
0.79
Negative
Market Momentum
MACD
0.01
Negative
RSI
53.22
Neutral
STOCH
64.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACET, the sentiment is Positive. The current price of 0.71 is above the 20-day moving average (MA) of 0.69, above the 50-day MA of 0.70, and below the 200-day MA of 0.79, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 53.22 is Neutral, neither overbought nor oversold. The STOCH value of 64.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACET.

Adicet Bio Risk Analysis

Adicet Bio disclosed 2 risk factors in its most recent earnings report. Adicet Bio reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks

Adicet Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
$343.02M3.71108.21%18.01%306.76%
51
Neutral
$7.91B-0.36-41.70%2.23%23.45%-1.86%
51
Neutral
127.51%56.94%
51
Neutral
$58.93M2.40-143.89%-98.56%-347.81%
41
Neutral
$149.39M-23.76%-100.00%55.32%
36
Underperform
$42.15M-47.87%18.86%
27
Underperform
$61.14M-64.39%48.45%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ACET
Adicet Bio
0.71
-0.73
-50.69%
BLUE
Bluebird Bio
4.97
-6.40
-56.29%
CTMX
CytomX Therapeutics
2.10
0.92
77.97%
DTIL
Precision BioSciences
5.03
-4.70
-48.30%
IMA
ImageneBio
13.72
-6.20
-31.12%
ACRV
Acrivon Therapeutics, Inc.
1.30
-6.76
-83.87%

Adicet Bio Corporate Events

Executive/Board Changes
Adicet Bio Appoints Michael Grissinger to Board
Positive
Apr 17, 2025

On April 17, 2025, Adicet Bio announced the appointment of Michael Grissinger to its Board of Directors. Grissinger, with over four decades of experience in pharmaceutical business development and strategic transactions, is expected to bring valuable insights to Adicet as it advances its gamma delta T cell platform. His extensive background, particularly in immunology, will be instrumental in guiding the company’s growth and development of therapies for autoimmune and solid tumor indications.

Spark’s Take on ACET Stock

According to Spark, TipRanks’ AI Analyst, ACET is a Underperform.

Adicet Bio faces significant financial challenges with no revenue and consistent losses, presenting major risk factors. The technical analysis suggests a bearish trend, while poor valuation due to a negative P/E ratio further impacts the stock’s attractiveness. Without improvement in revenue and cash flow management, the outlook remains concerning.

To see Spark’s full report on ACET stock, click here.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 21, 2025